OSI Pharmaceuticals to Provide a Summary of Data Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Me...
27 May 2009 - 12:00AM
Business Wire
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today announced it will
host a live webcast to provide a summary of the Company�s data,
including its flagship product Tarceva� (erlotinib), presented
during the 2009 American Society of Clinical Oncology (ASCO) Annual
Meeting in Orlando, FL. The webcast will be hosted by Colin
Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals and
OSI's Oncology Management Team. The webcast will begin at 7:30AM
Eastern Time on Tuesday, June 2, 2009.
To access the live webcast via the internet, please log on to
www.osip.com approximately 15 minutes before the start of the event
to allow for any software downloads that may be necessary.
Following the webcast, an archive will be available at the same
address for fourteen days.
About OSI Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and
changing lives" by discovering, developing and commercializing
high-quality, novel and differentiated personalized medicines
designed to extend life and improve the quality of life for
patients with cancer and diabetes/obesity. For additional
information about OSI, please visit http://www.osip.com.
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ
materially from the statements made. Factors that might cause such
a difference include, among others, OSI's and its collaborators'
abilities to effectively market and sell Tarceva and to expand the
approved indications for Tarceva, OSI's ability to protect its
intellectual property rights, safety concerns regarding Tarceva,
competition to Tarceva and OSI's drug candidates from other
biotechnology and pharmaceutical companies, the completion of
clinical trials, the effects of FDA and other governmental
regulation, including pricing controls, OSI's ability to
successfully develop and commercialize drug candidates, and other
factors described in OSI Pharmaceuticals' filings with the
Securities and Exchange Commission.
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Osi Pharmaceuticals Inc. (MM) (NASDAQ): 0 recent articles
More OSI Pharmaceuticals, Inc. News Articles